About: Zymergen

An Entity of Type: Subsidiary, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Zymergen is an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. Shortly after going public in 2021, it was reported that the company was facing difficulties in manufacturing products and struggling to make revenue. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million.

Property Value
dbo:abstract
  • ザイマージェン（英: Zymergen Inc. ）は、アメリカ合衆国カリフォルニア州エメリービルに本社を置くバイオテクノロジー企業。ゲノミクスと機械学習を応用した遺伝子組換え微生物の設計、製造および研究を手がけている。 (ja)
  • Zymergen is an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. Shortly after going public in 2021, it was reported that the company was facing difficulties in manufacturing products and struggling to make revenue. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million. (en)
dbo:foundingYear
  • 2013-01-01 (xsd:gYear)
dbo:industry
dbo:keyPerson
dbo:locationCity
dbo:parentCompany
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 69616363 (xsd:integer)
dbo:wikiPageLength
  • 13044 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1122462443 (xsd:integer)
dbo:wikiPageWikiLink
dbp:hqLocationCity
dbp:hqLocationCountry
  • U.S. (en)
dbp:industry
dbp:keyPeople
dbp:name
  • Zymergen Inc. (en)
dbp:parent
dbp:tradedAs
  • NASDAQ:ZY (en)
dbp:type
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • ザイマージェン（英: Zymergen Inc. ）は、アメリカ合衆国カリフォルニア州エメリービルに本社を置くバイオテクノロジー企業。ゲノミクスと機械学習を応用した遺伝子組換え微生物の設計、製造および研究を手がけている。 (ja)
  • Zymergen is an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. Shortly after going public in 2021, it was reported that the company was facing difficulties in manufacturing products and struggling to make revenue. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million. (en)
rdfs:label
  • ザイマージェン (ja)
  • Zymergen (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Zymergen Inc. (en)
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License